BACKGROUND: Few studies have assessed associations between craving and subsequent opioid use. We prospectively evaluated the relative utility of two craving questionnaires to predict opioid use among opioid-dependent patients in outpatient treatment. METHOD:Opioid-dependent patients (n = 147) initiating buprenorphine treatment were assessed every two weeks for 3 months. Craving was measured using the: (1) Desires for Drug Questionnaire (DDQ) and (2) Penn Alcohol-Craving Scale adapted for opioid craving (PCS). Multi-level logistic regression models estimated the effects of craving on the likelihood of opioid use. Craving assessed at time t was entered as a time-varying predictor of opioid use at time t + 1. RESULTS:Craving scores plateaued at approximately 2 weeks after initiation of buprenorphine. In adjusted regression models, a 1-point increase in PCS scores (on a 7-point scale) was associated with a significant increase in the odds of opioid use at the subsequent assessment (OR = 1.27, 95% CI 1.08; 1.49, p < 0.01). The odds of opioid use at the subsequent follow-up assessment increased significantly as DDQ desire and intention scores increased (OR = 1.25, 95%CI 1.03; 1.51, p < 0.05), but was not significantly associated with DDQ negative reinforcement (OR = 1.01, 95%CI 0.88; 1.17, p > 0.05) or DDQ control (OR = 0.97, 95%CI 0.85; 1.11, p > 0.05) scores. CONCLUSION: Self-reported craving for opioids was modestly associated with subsequent relapse to opioid use among a cohort of patients treated with buprenorphine. Assessment of craving may provide clinical utility in predicting relapse among treated opioid-dependent patients.
RCT Entities:
BACKGROUND: Few studies have assessed associations between craving and subsequent opioid use. We prospectively evaluated the relative utility of two craving questionnaires to predict opioid use among opioid-dependent patients in outpatient treatment. METHOD: Opioid-dependent patients (n = 147) initiating buprenorphine treatment were assessed every two weeks for 3 months. Craving was measured using the: (1) Desires for Drug Questionnaire (DDQ) and (2) Penn Alcohol-Craving Scale adapted for opioid craving (PCS). Multi-level logistic regression models estimated the effects of craving on the likelihood of opioid use. Craving assessed at time t was entered as a time-varying predictor of opioid use at time t + 1. RESULTS: Craving scores plateaued at approximately 2 weeks after initiation of buprenorphine. In adjusted regression models, a 1-point increase in PCS scores (on a 7-point scale) was associated with a significant increase in the odds of opioid use at the subsequent assessment (OR = 1.27, 95% CI 1.08; 1.49, p < 0.01). The odds of opioid use at the subsequent follow-up assessment increased significantly as DDQ desire and intention scores increased (OR = 1.25, 95%CI 1.03; 1.51, p < 0.05), but was not significantly associated with DDQ negative reinforcement (OR = 1.01, 95%CI 0.88; 1.17, p > 0.05) or DDQ control (OR = 0.97, 95%CI 0.85; 1.11, p > 0.05) scores. CONCLUSION: Self-reported craving for opioids was modestly associated with subsequent relapse to opioid use among a cohort of patients treated with buprenorphine. Assessment of craving may provide clinical utility in predicting relapse among treated opioid-dependent patients.
Authors: Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson Journal: Addiction Date: 2011-10-07 Impact factor: 6.526
Authors: Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2010-07-03
Authors: W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal Journal: Addiction Date: 1998-04 Impact factor: 6.526
Authors: Kenzie L Preston; William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; David H Epstein Journal: Psychopharmacology (Berl) Date: 2017-06-08 Impact factor: 4.530
Authors: Michael D Stein; Debra S Herman; Ethan Moitra; Jacki Hecht; Rosalie Lopez; Bradley J Anderson; Richard A Brown Journal: Drug Alcohol Depend Date: 2014-11-26 Impact factor: 4.492
Authors: David M Lydon-Staley; H Harrington Cleveland; Andrew S Huhn; Michael J Cleveland; Jonathan Harris; Dean Stankoski; Erin Deneke; Roger E Meyer; Scott C Bunce Journal: Addict Behav Date: 2016-08-15 Impact factor: 3.913
Authors: Judith I Tsui; Marlene C Lira; Debbie M Cheng; Michael R Winter; Daniel P Alford; Jane M Liebschutz; Robert R Edwards; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2016-06-27 Impact factor: 4.492
Authors: Kenzie L Preston; William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; David H Epstein Journal: Neuropsychopharmacology Date: 2017-11-06 Impact factor: 7.853
Authors: Lindsay M Lueptow; Elizabeth C Shashkova; Margaret G Miller; Christopher J Evans; Catherine M Cahill Journal: Curr Anesthesiol Rep Date: 2020-09-29